Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions

  title={Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions},
  author={Marilyn H. Kelly and Beth A. Brillante and M. T. Collins},
  journal={Osteoporosis International},
SummaryTo determine the prevalence, distribution, age-related changes and treatment of pain in fibrous dysplasia, we studied 78 children and adults. Pain was common, more prevalent and intense in adults, sometimes requiring narcotic analgesia. It was often untreated, especially in children, and surprisingly severity did not correlate with skeletal disease burden.IntroductionPain is common in fibrous dysplasia (FD), but relatively unstudied. We studied a well-characterized population of patients… 
Pain in fibrous dysplasia: relationship with anatomical and clinical features
The data suggest that almost 50% of patients with FD report pain at FD sites, thus representing a major clinical manifestation of the disorder, importantly also in patients with monostotic lesions.
Preliminary Results of Curettage and Cementation in the Treatment of Fibrous Dysplasia of the Proximal Radius
To use curettage and cementation as a control method of Fibrous dysplasia of the proximal radius, a relatively common, benign developmental skeletal disorder, female patients may have an increase in pain or even an increased tendency to fracture during and immediately after pregnancy, and treatment is mainly palliative.
Pathophysiology and medical treatment of pain in fibrous dysplasia of bone
The mechanism of bone pain in FD remains uncertain, but by analogy with bone tumors one may consider that ectopic sprouting and formation of neuroma-like structures by sensory and sympathetic nerve fibers also occur in the dysplastic skeleton.
Case Report: The Imperfect Association Between Craniofacial Lesion Burden and Pain in Fibrous Dysplasia
Two adult females with comparable craniofacial FD lesion size and location are presented, as measured by 18F-sodium fluoride positron emission tomography/computed tomography (PET/CT), yet their respective pain phenotypes differed significantly.
Determinants of impaired quality of life in patients with fibrous dysplasia
BackgroundFibrous dysplasia is a rare bone disorder, commonly associated with pain, deformity and fractures, which may significantly impact on quality of life. In this study we evaluate quality of
Natural History and Progression of Craniofacial Fibrous Dysplasia: A Retrospective Evaluation of 114 Patients From Massachusetts General Hospital.
  • K. Sweeney, L. Kaban
  • Medicine
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • 2020
Monostotic fibrous dysplasia of the proximal femur: natural history and predisposing factors for disease progression.
The natural history and predisposing factors for progression of dysplasia in a group of 76 patients with a mean follow-up of 8.5 years were investigated, finding an initial presentation of pain, a limp, radiological evidence of microfracture, and younger age (< 17 years) were significant predispose factors for disease progression.
The Hip in Fibrous Dysplasia
The managed of FD of the proximal femur aims at preventing pathologic fracture, deformity correction, and pain control, and once skeletal maturity is reached the disease process tends to stabilize or may normalize in select patients.
Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study
In a national referral center for FD, one patient on follow‐up out of six had incident fracture, and in the multivariate model, the polyostotic form and bisphosphonate use remained significant predictors.
Age‐Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone
  • P. Florenzano, Kristen S. Pan, A. Boyce
  • Medicine, Biology
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2019
FD is associated with an age‐dependent decline in bone turnover and other markers of disease activity and its association with pain, which should be considered when evaluating use and response to bisphosphonates in patients being treated for FD and in any study using BTMs as surrogate endpoints.


Fibrous dysplasia. Pathophysiology, evaluation, and treatment.
Bisphosphonate therapy may help to improve function, decrease pain, and lower fracture risk in appropriately selected patients with fibrous dysplasia.
Long‐Term Effects of Intravenous Pamidronate in Fibrous Dysplasia of Bone
It is suggested that intravenous pamidronate alleviates bone pain, reduces the rate of bone turnover assessed by biochemical markers, and improves radiological lesions of FD.
Natural history and treatment of fibrous dysplasia of bone: a multicenter clinicopathologic study promoted by the European Pediatric Orthopaedic Society
A multicenter study on fibrous dysplasia of bone (FD) was promoted by the European Pediatric Orthopaedic Society in 1999 in order to gain insight into the natural history of the disease and to
[Fibrous dysplasia].
The lesions of fibrous dysplasia are difficult to treat, and Enneking and Gearen recommended replacement of the lesion with cortical allograft, which would resist absorption by the host bone and provide structural stability.
Pamidronate treatment of bone fibrous dysplasia in nine children with McCune‐Albright syndrome
Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune‐Albright syndrome and demonstrates drug activity at the lesional level.
Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
Pamidronate therapy appears to be safe in children and adolescents with polyostotic FD, however, it is found no clear evidence that pamidRONate has an effect on dysplastic lesions in such patients.
[Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
  • R. Chapurlat, P. Meunier
  • Medicine, Engineering
    Revue de chirurgie orthopedique et reparatrice de l'appareil moteur
  • 1998
Bisphosphonates are a breakthrough in Paget's disease of bone, fibrous dysplasia of bone and osteoporosis and reduce very significantly the subsequent risk of vertebral, femoral and lower forearm fractures.
Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
Pamidronate treatment is an effective therapeutic modality for children with polyostotic fibrous Dysplasia, with a good short-term safety profile, and failure to demonstrate major biochemical or bone densitometry improvements is due to the nature of the fibrous dysplasia and intercurrent microfracture.